Re­al-world ev­i­dence on Gilead­'s HIV com­bo Bik­tarvy con­firms high ef­fi­ca­cy; Dig­i­tal ther­a­peu­tics firm to trade on Nas­daq

Gilead on Fri­day an­nounced in­ter­im re­sults from an on­go­ing, re­al-world tri­al for its HIV drug Bik­tarvy, con­firm­ing its ef­fec­tive­ness in more than 1,100 peo­ple liv­ing with HIV, and an­a­lyz­ing pa­tient-re­port­ed out­comes too.

The FDA ap­proved Bik­tarvy in 2018, based on da­ta from four Phase III stud­ies.

In this lat­est ob­ser­va­tion­al study, treat­ment with Bik­tarvy oc­curred be­tween June 2018 and Sep­tem­ber 2020, and af­ter 12 months of Bik­tarvy, the vast ma­jor­i­ty of treat­ment-naive adults and treat­ment-ex­pe­ri­enced adults liv­ing with HIV — 97% and 96%, re­spec­tive­ly —  achieved and main­tained vi­ro­log­ic sup­pres­sion (HIV-1 RNA <50 copies/mL).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER